Dr. Schmidt on the Utilization of Bispecific Antibodies in Myeloma

Timothy M. Schmidt, MD, an assistant professor of the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses the utilization of bispecific antibodies in myeloma.

Bispecific antibodies are a promising off-the-shelf treatment option that have been developed to engage the immune system in patients with relapsed/refractory multiple myeloma or other hematologic malignancies, according to Schmidt. Similar to CAR T-cell therapies, bispecific products activate T cells and bring them in close proximity of cancer cells; this allows the agent to recognize when cells are abnormal and induce cell death, concludes Schmidt.